Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: Activation theory revisited

Biochemical Pharmacology

Volumn 58, Issue 10, 1999, Pages 1625-1629

  Natarajan, Ganesan ^a   Malathi, R ^a   Holler, Eggehard ^b  

^a Dr ALM Postgraduate Institute of Basic Medical Sciences   (India)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Carboplatin; Drug activation; MCF 7 extract; Platinum metabolism; Platinum DNA; Sulfhydryl groups

Indexed keywords

CARBOPLATIN; CELL EXTRACT; THIOUREA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA BINDING; DRUG ACTIVATION; DRUG METABOLISM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBOPLATIN; CELL EXTRACTS; DNA; ETHIDIUM; FLUORESCENCE; HUMANS; METHIONINE; TUMOR CELLS, CULTURED;

EID: 0032879419     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00250-6     Document Type: Article

References (24)

1. Knox R.J., Friedlos F., Lydall D.A., Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs Evidence that cis-diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA . Cancer Res. 46:1986;1972-1979.
2. Calvert A.H., Harland S.J., Newell D.R., Siddik Z.H., Jones A.C., McElwain T.J., Raju S., Wiltshaw E., Smith I.E., Baker J.M., Peckham M.J., Harrap K.R. Early clinical studies with cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II). Cancer Chemother Pharmacol. 9:1982;140-147.
3. Sherman S., Lippard S.J. Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev. 87:1987;1153.
4. Bellon S.F., Coleman J.H., Lippard S.J. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 30:1991;8026-8035.
5. Malinge J.M., Perez C., Leng M. Base sequence-independent distortions induced by interstrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA. Nucleic Acids Res. 22:1994;3834-3839.
6. Bernges D., örner G., Holler E. Escherichia coli DNA polymerase I Inherent exonuclease activities differentiate between monofunctional and bifunctional adducts of DNA and cis- or trans-diamminedichloroplatinum(II). An exonuclease investigation of the kinetics of the adduct formation . Eur J Biochem. 191:1990;743-753.
7. Plooy A.C.M., van Dijk M., Lohman P.H.M. Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 44:1984;2043-2051.
8. Pil M.P., Lippard S.J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science. 256:1992;234-237.
9. Billings P.C., Davis R.J., Engelsberg B.N., Skov K.A., Hughes E.N. Characterization of high mobility group protein binding to cisplatin-damaged DNA. Biochem Biophys Res Commun. 188:1992;1286-1294.
10. Hongo Aseki S., Akiyama K., Kudo T. A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. Int J Biochem. 26:1994;1009-1016.
11. Los G., Verdegaal E., Noteborn H.P., Ruevekamp M., de Graeff A., Meesters E.W., ten Bokkel-Huinink D., McVie J.G. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol. 42:1991;357-363.
12. Terheggen P.M., Dijkman R., Begg A.C., Dubbelman R., Floot B.G., Hart A.A., den Engelse L. Monitoring of interaction products of cis-diammine dichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res. 48:1988;5597-5603.
13. Cleare M.J., Hydes P.C., Malerbi B.W. Anti-tumor platinum complexes Relationship between chemical properties and activity . Biochimie. 60:1978;835-850.
14. 2(CBDCA-O)(5′-GMP-N7)] in solution . Inorg Chem. 32:1993;1333-1340.
15. 2(L-methionine-S)] Ring-opened adduct of the anticancer drug carboplatin ("paraplatin"). Detection of a similar complex in urine by NMR spectroscopy . J Am Chem Soc. 116:1994;11175-11176.
16. Blommaert F.A., van Dijk-Knijnenburg H.C., Dijt F.J., den Engelse L., Baan R.A., Berends F., Fichtinger-Schepman A.M. Formation of DNA adducts by the anticancer drug carboplatin Different nucleotide sequence preferences in vitro and in cells . Biochemistry. 34:1995;8474-8480.
17. Howe-Grant M.E., Lippard S.J. Aqueous platinum(II) chemistry; binding to biological molecules. Sigel H. Metal Ions in Biological Systems Vol. 1980;pp. 63-125. Dekker, New York.
18. Howe-Grant M., Wu K., Bauer W.R., Lippard S.J. Binding of platinum and palladium metallointercalation reagent and antitumor drugs to closed and open DNAs. Biochemistry. 15:1976;4339-4346.
19. Evans B.D., Raju K.S., Calvert A.H., Harland S.J., Wiltshaw E. Phase II study of JMB, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 67:1983;997-1000.
20. Harland S.J., Newell D.R., Siddik Z.H., Chadwick R., Calvert A.H., Harrap K.R. Pharmacokinetics of cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) in patients with normal and impaired renal function. Cancer Res. 44:1984;1693-1697.
21. Eisenberger M., Van Echo D., Aisner J. Carboplatin the experience in head and neck cancer . Semin Oncol. 16:(Suppl 5):1987;34-41.
22. Kavanagh J.J., Nicaise C. Carboplatin in refractory epithelial ovarian cancer. Semin Oncol. 16:(Suppl 5):1987;45-48.
23. Tamura T., Shinkai T., Eguchi K., Sasaki Y., Fujiwara Y., Fukuda M., Ohe Y., Nakagawa K., Mikato K., Saijo N. Phase II study of carboplatin in the non-small cell lung cancer. J Clin Oncol. 19:1989;51-55.
24. Lindauer E., Holler E. Cellular distribution and cellular reactivity of platinum(II) complexes. Biochem Pharmacol. 52:1996;7-14.